関: lercanidipine hydrochloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/10/20 07:56:51」(JST)

wiki en

Lercanidipine is a calcium channel blocker of the dihydropyridine class,which works by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. It is sold under various commercial names including Zanidip. This lowers the blood pressure and allows the heart to work more efficiently.^[1]

References[edit]

^ Barrios, V; Escobar, C; Navarro, A; Barrios, L; Navarro-Cid, J; Calderón, A; Laura, Investigators (2006). "Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study". International journal of clinical practice 60 (11): 1364–70. doi:10.1111/j.1742-1241.2006.01176.x. PMC 1636683. PMID 17073834.

External links[edit]

DDB 31597

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

English Journal

Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.

Derosa G1, Mugellini A2, Querci F3, Franzetti I4, Pesce RM2, D'Angelo A2, Maffioli P5.
Scientific reports.Sci Rep.2015 Aug 5;5:12603. doi: 10.1038/srep12603.
The aim of this study was to evaluate the effects of lercanidipine or barnidipine on echocardiographic parameters, in hypertensive, type 2 diabetics with left ventricular hypertrophy. One hundred and forty-four patients were randomized to lercanidipine, 20 mg/day, or barnidipine, 20 mg/day, in a
PMID 26243165

Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial.

Na SH1, Lee HY1, Hong Baek S2, Jeon HK3, Kang JH4, Kim YN5, Park CG6, Ryu JK7, Rhee MY8, Kim MH9, Hong TJ10, Choi DJ11, Cho SW12, Cha DH13, Jeon ES14, Kim JJ15, Shin JH16, Park SH17, Lee SH18, John SH19, Shin ES20, Kim NH21, Lee SY22, Kwan J23, Jeong MH24, Kim SW25, Jeong JO26, Kim DW27, Lee NH28, Park WJ29, Ahn JC30, Won KH31, Uk Lee S32, Cho JH33, Kim SK34, Ahn T35, Hong S36, Yoo SY37, Kim SY38, Kim BS39, Juhn JH40, Kim SY40, Lee YJ40, Oh BH1.
Clinical therapeutics.Clin Ther.2015 Aug 1;37(8):1726-39. doi: 10.1016/j.clinthera.2015.05.512. Epub 2015 Jul 8.
PURPOSE: The objective of this study was to evaluate the efficacy and safety of the lercanidipine/valsartan combination compared with lercanidipine monotherapy in patients with hypertension.METHODS: Part 1 of this study was the randomized, multicenter, double-blind, parallel group, Phase III, 8-week
PMID 26164786

Bullous Eruption Associated With Dihydropyridines With Cross Reactivity.

Charfi O1, Lakhoua G2, Sahnoun R2, Daghfous R2, El Aidli S2, Kastalli S2, Zaïem A2.
Thérapie.Therapie.2015 Jul-Aug;70(4):381-3. doi: 10.2515/therapie/2015023. Epub 2015 May 8.
The spectrum of cutaneous eruptions associated with dihydropyridines is extensive, varying from exanthemas to severe adverse events. We report a case of bullous eruption, one month after starting nicardipine and lercanidipine. The same symptoms recurred few days after taking nitrendipine. © 2015 So
PMID 25957434

Japanese Journal

Lercanidipine Rescues Hippocampus Pyramidal Neurons from Mild Ischemia-Induced Delayed Neuronal Death in SHRSP.

Sakurai-Yamashita Yasuko,Harada Noboru,Niwa Masami
Cellular and molecular neurobiology 31(4), 561-567, 2011-05
… This study was designed to compare the effects of the antihypertensive drugs lercanidipine, nicardipine, lisinopril, valsartan, and hydralazine on occlusion-induced DND in SHRSPs. … 0.1% Nicardipine and 0.01 or 0.03% lercanidipine were administered in the SP diet (about 61.3, 5.7, and 18.8 mg/kg/day, respectively), and the remaining drugs were administered at 10 mg/kg/day using the mini-osmotic pump. …
NAID 120002835141

Antianginal Effects of Lercanidipine on the Vasopressin or Methacholine Induced Anginal Model in Rats(Pharmacology)

Sasaki Toshinobu,Maruyama Hirofumi,Kase Yoshio [他],TAKEDA Shuichi,ABURADA Masaki
Biological & pharmaceutical bulletin 28(5), 811-816, 2005-05-01
… The antianginal effects of lercanidipine, a newly synthesized 1,4-dihydropyridine derivative calcium channel antagonist, were evaluated in experimental angina model rats and the effects were compared with those of nifedipine, benidipine and amlodipine. … In the vasopressin-induced angina model, intravenous administration of lercanidipine dose-dependently suppressed vasopressin-induced ST-depression. …
NAID 10016663116

Enantioselective pharmacokinetics of lercanidipine in healthy volunteers

JABOR Valquiria Aparecida Polisel,COELHO Eduardo Barbosa,LANCHOTE Vera Lucia
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 813(1), 343-346, 2004-11-25
NAID 10016540879

Related Pictures

★リンクテーブル★

リンク元	「レルカニジピン」
拡張検索	「lercanidipine hydrochloride」

「レルカニジピン」

Lercanidipine
Systematic (IUPAC) name
	2[(3,3-diphenylpropyl)(methyl)amino]-1,1-dimethylethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	100427-26-7
ATC code	C08CA13
PubChem	CID 65866
DrugBank	DB00528
ChemSpider	59276
UNII	V7XTJ4R0BH
KEGG	D08111
ChEMBL	CHEMBL250270
Chemical data
Formula	C36H41N3O6
Mol. mass	611.727 g/mol
	SMILES [O-][N+](=O)c1cccc(c1)C4C(=C(/N\C(=C4\C(=O)OC(C)(C)CN(CCC(c2ccccc2)c3ccccc3)C)C)C)\C(=O)OC;
	InChI InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3 ; Key:ZDXUKAKRHYTAKV-UHFFFAOYSA-N ;
(what is this?) (verify);